Clinical trials: Protein Digestion
Pancreatic Ductal Adenocarcinoma, Gastric Cancer
Lead-212 PSV359 Therapy for Patients With Solid Tumors
Phase I/IIa image-guided, alpha-particle therapy study of [203Pb]Pb-PSV359 and [212Pb]Pb-PSV359 in patients with solid tumors that are known to be Fibroblast Activation Protein (FAP)-positive.
- Conditions
- Pancreatic Ductal Adenocarcinoma, Gastric Cancer, Esophageal Cancer, Colorectal Cancer
- Trial name
- NCT06710756
- Testing
- [203Pb]Pb-PSV359, [212Pb]Pb-PSV359
- Where
- 16 sites in United States
- Volunteers
- 112 people
- Sponsor
- Perspective Therapeutics
Chronic Hepatitis C
Albinterferon Alfa 2b Single Dose in Japanese Chronic Hepatitis C Patients
This study will evaluate safety, tolerability, pharmacokinetics and pharmacodynamics of albinterferon alfa 2b (alb-IFN) single dose in Japanese chronic hepatitis C patients
- Trial name
- NCT00724776
- Testing
- Albinterferon alfa 2b
- Where
- Japan
- Volunteers
- 30 people
- Sponsor
- Novartis
Advanced Solid Tumor, Metastatic Cancer
Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers
The purpose of the Phase 1/2a study is to evaluate the safety and tolerability of SNK01 in combination with trastuzumab or cetuximab in order to determine the maximum tolerated dose (MTD)/recommended Phase 2 dose (RP2D), and the…
- Conditions
- Advanced Solid Tumor, Metastatic Cancer, HER2-positive Breast Cancer, HER2-positive Gastric Cancer
- Trial name
- NCT04464967
- Testing
- SNK01, Trastuzumab, Cetuximab
- Sponsor
- NKGen Biotech, Inc.
Solid Tumors, Colorectal Cancer
L19TNFα in Patients With Advanced Solid Tumors
The recombinant human fusion protein L19TNFα was created with the intention to overcome the systemic toxicity of TNFα by directly targeting it to tumor tissues.
- Trial name
- NCT01253837
- Testing
- L19TNFa
- Where
- 2 sites in Italy
- Volunteers
- 34 people
- Sponsor
- Philogen S.p.A.
Malnutrition, Malabsorption
High Energy High Protein Peptide Feed Study
Oral nutritional supplements and enteral tube feeds are commonly used to meet the nutritional requirements of patients with disease-related malnutrition, or who require medical nutrition support for other reasons.
- Trial name
- NCT03140371
- Testing
- High energy high protein peptide feed study
- Where
- 10 sites in United Kingdom
- Volunteers
- 20 people
- Sponsor
- Nutricia UK Ltd
Main Focus: Gluten and Starch Digestibility
Digestion of Gluten in the Presence of Enzymes
This study evaluates the impact of two dietary supplements (Elevase® and DE111®) and of oatmeal properties on the digestion of gluten and starch and on the glycemic response.
- Trial name
- GlutDigest (NCT04489810)
- Testing
- Elevase®, DE111®, Meal A
- Where
- Ireland
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- The Archer-Daniels-Midland Company
Cow's Milk Protein Allergy, Eosinophilic Gastrointestinal Disorders
A Study to Monitor the Use of an Amino Acid-Based Infant Formula
To assess the frequency and nature of adverse events in infants fed a free amino acid based infant formula.
- Conditions
- Cow's Milk Protein Allergy, Eosinophilic Gastrointestinal Disorders, Malabsorption/Maldigestion, Short Bowel Syndrome
- Trial name
- EAGLE (NCT02953223)
- Testing
- Free amino acid infant formula
- Where
- 29 sites in United States
- Volunteers
- 144 people
- Sponsor
- Société des Produits Nestlé (SPN)
Pancreatic Ductal Adenocarcinoma, Colorectal Cancer
FAPi Radioligand OpeN-Label, Phase 1 Study to Evaluate Safety, Tolerability and DosImetry of [Lu-177]-PNT6555; A Dose Escalation Study for TReatment of Patients With Select Solid Tumors (FRONTIER)
This Phase 1 study will evaluate the safety and tolerability of [Ga-68]-PNT6555 and [Lu-177]-PNT6555 in subjects with select solid tumors that have FAP over-expression, in order to determine a recommended Phase 2 dose.
- Conditions
- Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, Esophageal Cancer, Melanoma (Skin)
- Trial name
- NCT05432193
- Testing
- [Ga-68]-PNT6555, [Lu-177]-PNT6555
- Where
- 4 sites in United States, Canada
- Volunteers
- 20 people
- Sponsor
- POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company
Hepatitis C, Chronic
KW-136 With Sofosbuvir for Chinese Adults With Chronic Hepatitis C
This study aimed to confirm efficacy and safety of KW-136, an investigational anti-hepatitis C virus (HCV) drug, combined with sofosbuvir for treatment of naive and experienced adults chronically infected with HCV.
- Trial name
- KW-136_III (NCT03995485)
- Testing
- KW-136 capsule, Sofosbuvir
- Where
- 19 sites in China
- Volunteers
- 371 people
- Sponsor
- Kawin Technology Share-holding Co., Ltd.
Hepatitis B Virus
Study of Recombinant Human Serum Albumin/Interferon alpha2b Fusion Protein in Hepatitis B Patient
The purpose of this study is to evaluate the dosages of recombinant human serum albumin/interferon alpha2b fusion protein injection on HBV subjects.
- Trial name
- NCT03294798
- Testing
- Human Serum Albumin/interferon alpha2b fusion protein, Pegasys
- Where
- China
- Volunteers
- 11 people
- Sponsor
- Tianjin SinoBiotech Ltd.
Hepatitis C
A Study of Albuferon With Ribavirin in Interferon Treatment Experienced Subjects With Chronic Hepatitis C
This is a Phase 2, multi-center, randomized, open-label study to evaluate the safety, tolerability, and efficacy of Albuferon in subjects with hepatitis C (HEP C) who failed to respond to previous interferon alfa therapy.
- Trial name
- NCT00097435
- Testing
- Albuferon, Ribavirin
- Where
- 8 sites in United States
- Volunteers
- 115 people
- Sponsor
- Human Genome Sciences Inc.
Gut Health, Gastrointestinal Diseases
Improved Gut Health Outcomes Associated With Probiotics Fortified With Hydrolyzed Whey Protein in Infant Formula
The goal of this interventional clinical trial is to test the effectiveness of improving gut health in terms of frequency of bowel movements in newly born infants fed with Feihe investigational formula product containing…
- Trial name
- NCT06159088
- Testing
- Feihe Investigational Formula, Control Formula, Breastfeeding
- Where
- 3 sites in China
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Heilongjiang Feihe Dairy Co. Ltd.
Advanced Solid Tumor, Metastatic Solid Tumor
A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and therapeutic activity of GI-102 as a single agent and in combination with conventional anti-cancer drugs, pembrolizumab or trastuzumab…
- Conditions
- Advanced Solid Tumor, Metastatic Solid Tumor, Soft Tissue Sarcoma (STS), Platinum-resistant Ovarian Cancer (PROC)
- Trial name
- NCT05824975
- Testing
- GI-102 subcutaneous (SC), GI-102, doxorubicin
- Where
- 11 sites in United States, South Korea
- Volunteers
- 358 people
- Sponsor
- GI Innovation, Inc.
Venous Thromboembolism
Non Interventional Study of the Validation of the Ottawa Score in Cancer Patients With Venous Thromboembolism (VTE)
The purpose of this study is to validate the Ottawa score (risk of thromboembolic recurrences) in cancer patients with thromboembolic disease treated with tinzaparin (Innohep®)
- Trial name
- PREDICARE (NCT03099031)
- Testing
- Tinzaparin
- Where
- France
- Volunteers
- 420 people
- Sponsor
- LEO Pharma
Endometrial Cancer, Gastric Cancer
Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
TROPION-PanTumor03 will investigate the safety, tolerability, and anti-tumour activity of Datopotamab Deruxtecan (Dato-DXd) as Monotherapy and in Combination with Anticancer Agents in Patients with Advanced/Metastatic Solid…
- Conditions
- Endometrial Cancer, Gastric Cancer, Metastatic Castration-resistant Prostate Cancer, Ovarian Cancer
- Trial name
- NCT05489211
- Testing
- Datopotamab deruxtecan (Dato-DXd), Capecitabine, 5-Fluorouracil
- Where
- 96 sites in United States, Canada and 12 more
- Volunteers
- 454 people
- Sponsor
- AstraZeneca
Peritoneal Carcinomatosis
A Phase I Study Evaluating SCB-313 for the Treatment of Subjects With Peritoneal Carcinomatosis
To evaluate the safety and tolerability of SCB-313 in patients with peritoneal carcinomatosisa, to determine the maximum tolerated dose (MTD) and/or extended study recommended dose (RDE) for SCB-313 intraperitoneal injection…
- Trial name
- NCT04047771
- Testing
- SCB-313
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Sichuan Clover Biopharmaceuticals, Inc.
Ulcerative Colitis (Disorder), Crohn Disease
Partial Enteral Nutrition to Prevent Weight Loss and Sarcopenia in IBD Patients at Nutritional Risk - SIMBA
This is a multicenter, open-label, randomized two-arm interventional nutritional study evaluating the effects of partial enteral nutrition (LH VIOLA) in patients with Inflammatory Bowel Disease (IBD) at risk of malnutrition.
- Conditions
- Ulcerative Colitis (Disorder), Crohn Disease, Malnutrition or Risk of Malnutrition, IBD
- Trial name
- SIMBA (NCT07433946)
- Testing
- LH VIOLA Supplementation
- Where
- 4 sites in Italy
- Volunteers
- 146 people
- Sponsor
- Lionhealth Srl Società Benefit
Head and Neck Squamous Cell Carcinoma (HNSCC), Non-small Cell Lung Cancer (NSCLC)
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
This is a First In Human (FIH), multicenter, open-label, Phase I/II study to evaluate safety, tolerability, Pharmacokinetics (PK), pharmacodynamics, and efficacy of MT-4561 in patients with advanced solid tumors.
- Conditions
- Head and Neck Squamous Cell Carcinoma (HNSCC), Non-small Cell Lung Cancer (NSCLC), Esophageal Cancer, Gastric Cancer
- Trial name
- NCT06943521
- Testing
- MT-4561
- Where
- 6 sites in United States, Japan
- Volunteers
- 27 people
- Sponsor
- Tanabe Pharma America, Inc.
Chronic Hepatitis b
A Phase II Study of Subcutaneously Injected PD-L1 Antibody ASC22 in Chronic Hepatitis B Patients
The objective of this study is to evaluate the safety and efficacy of ASC22 in the treatment of chronic hepatitis B after single and multiple drug administration.
- Trial name
- NCT04465890
- Testing
- ASC22, sodium chloride
- Where
- China
- Volunteers
- 207 people
- Sponsor
- Ascletis Pharmaceuticals Co., Ltd.
Gastric Cancer, Gastric Adenocarcinoma
Phase 1/2 Study of BHB810 in Advanced Gastric and GEJ Adenocarcinoma
This study is looking at how safe BHB810 is in adults with gastric and gastroesophageal adenocarcinoma (GEJ). The purpose of this study is also to look at: how well the study drug works, how the study drug moves into, through…
- Conditions
- Gastric Cancer, Gastric Adenocarcinoma, Gastric (Stomach) Cancer, Gastroesophageal Adenocarcinoma
- Trial name
- NCT07529808
- Testing
- BHB810
- Where
- 3 sites in United States
- Volunteers
- 164 people
- Sponsor
- BigHat Biosciences, Inc.